Top

Published in:

01-03-2015 | Original Article

Implications of pentraxin 3 levels in patients with acute aortic dissection

Authors: Kenshiro Arao, Takayuki Fujiwara, Yousuke Taniguchi, Hiroyuki Jinnouchi, Harue Sasai, Mitsunari Matsumoto, Hiroshi Funayama, Junya Ako, Shin-ichi Momomura

Published in: Heart and Vessels | Issue 2/2015

Abstract

Acute aortic dissection (AAD) causes transient inflammation with occasional pleural fluid (PF) accumulation. Although pentraxin 3 (PTX3) is a vascular inflammation-related biomarker, little is known about PTX3 levels in patients with AAD. We explored the serial changes in plasma PTX3 levels and the association of peak levels with the amount of PF accumulation. Consecutive patients (n = 41) with Stanford type B AAD were enrolled, and blood samples for the measurements of serum albumin, plasma PTX3 and high-sensitivity C-reactive protein (CRP) were collected daily until 7 days after symptom onset. PF accumulation on computed tomography imaging on the third hospital day was divided into 3 grades (I: none or slight, II: mild in the uni- or bilateral pleural cavity, III: moderate or more). PTX3 and CRP levels were analyzed after logarithmic transformation because of their skewed distributions. Peak PTX3 and CRP levels were observed at 4.3 ± 2.1 and 4.7 ± 2.0 days after symptom onset, and their values were 12.2 [interquartile range (IQR), 8.2–20.9] ng/mL and 12.0 (IQR, 8.6–15.2) mg/dL, respectively. On univariate analysis, the peak level of PTX3 had a negative correlation with the minimum level of serum albumin, and a positive correlation with PF grade and duration of intensive care unit stay. On multivariate analysis, the peak level of PTX3 was correlated with PF grade (P = 0.037). In conclusion, the peak level of PTX3 in patients with AAD was associated with the amount of transient PF accumulation, which may be associated with inflammatory vascular permeability.

Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843CrossRefPubMed

Bottazzi B, Vouret-Craviari V, Bastone A, De Gioia L, Matteucci C, Peri G, Spreafico F, Pausa M, D’Ettorre C, Gianazza E, Tagliabue A, Salmona M, Tedesco F, Introna M, Mantovani A (1997) Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272:32817–32823CrossRefPubMed

Mairuhu AT, Peri G, Setiati TE, Hack CE, Koraka P, Soemantri A, Osterhaus AD, Brandjes DP, van der Meer JW, Mantovani A, van Gorp EC (2005) Elevated plasma levels of the long pentraxin, pentraxin 3, in severe dengue virus infections. J Med Virol 76:547–552CrossRefPubMed

Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102:636–641CrossRefPubMed

Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A, Lipid Assessment Trial Italian Network (LATIN) Investigators (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110:2349–2354CrossRefPubMed

Soeki T, Bando S, Uematsu E, Matsuura T, Niki T, Ise T, Kusunose K, Hotchi J, Ueda Y, Tomita N, Yamaguchi K, Yagi S, Fukuda D, Taketani Y, Iwase T, Yamada H, Wakatsuki T, Shimabukuro M, Sata M (2013) Pentraxin 3 is a local inflammatory marker in atrial fibrillation. Heart Vessels. doi:10.1007/s00380-013-0400-8

He X, Han B, Liu M (2007) Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 292:L1039–L1049CrossRefPubMed

Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A (2008) Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 36:2302–2308CrossRefPubMed

Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM (2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 29:594–599CrossRefPubMedCentralPubMed

10.

Ryu WS, Kim CK, Kim BJ, Kim C, Lee SH, Yoon BW (2012) Pentraxin 3: a novel and independent prognostic marker in ischemic stroke. Atherosclerosis 220:581–586CrossRefPubMed

11.

Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K (2007) Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 130:19–22CrossRefPubMed

12.

Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, Sagara M, Miyamoto K, Satoh H, Kohno I, Kurata T, Ota H, Mantovani A, Hamakubo T, Daida H, Kodama T (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27:161–167CrossRefPubMed

13.

Kotooka N, Inoue T, Fujimatsu D, Morooka T, Hashimoto S, Hikichi Y, Uchida T, Sugiyama A, Node K (2008) Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 197:368–374CrossRefPubMed

14.

Sugano Y, Anzai T, Yoshikawa T, Satoh T, Iwanaga S, Hayashi T, Maekawa Y, Shimizu H, Yozu R, Ogawa S (2005) Serum C-reactive protein elevation predicts poor clinical outcome in patients with distal type acute aortic dissection: association with the occurrence of oxygenation impairment. Int J Cardiol 102:39–45CrossRefPubMed

15.

Sakakura K, Kubo N, Ako J, Wada H, Fujiwara N, Funayama H, Ikeda N, Nakamura T, Sugawara Y, Yasu T, Kawakami M, Momomura S (2010) Peak C-reactive protein level predicts long-term outcomes in type B acute aortic dissection. Hypertension 55:422–429CrossRefPubMed

16.

Okina N, Ohuchida M, Takeuchi T, Fujiyama T, Satoh A, Sakamoto T, Adachi H, Imaizumi T (2013) Utility of measuring C-reactive protein for prediction of in-hospital events in patients with acute aortic dissection. Heart Vessels 28:330–335CrossRefPubMed

17.

Yamasaki K, Kurimura M, Kasai T, Sagara M, Kodama T, Inoue K (2009) Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations. Clin Chem Lab Med 47:471–477CrossRefPubMed

18.

Arao K, Yasu T, Umemoto T, Jinbo S, Ikeda N, Ueda S, Kawakami M, Momomura S (2009) Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J 73:1523–1530CrossRefPubMed

19.

Jo Y, Anzai T, Sugano Y, Naito K, Ueno K, Kohno T, Yoshikawa T, Ogawa S (2008) Early use of beta-blockers attenuates systemic inflammatory response and lung oxygenation impairment after distal type acute aortic dissection. Heart Vessels 23:334–340CrossRefPubMed

20.

Morikawa S, Takabe W, Mataki C, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T (2004) Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 11:62–72CrossRefPubMed

21.

Akerfeldt T, Larsson T (2010) Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures. Inflammation 34:367–370CrossRef

22.

Garlanda C, Bottazzi B, Bastone A, Mantovani A (2005) Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 23:337–366CrossRefPubMed

23.

Mantovani A, Garlanda C, Bottazzi B (2003) Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21(Suppl 2):S43–S47CrossRefPubMed

24.

Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22:e10–e14CrossRefPubMed

25.

Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G, Mantovani A (2004) Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175:221–228CrossRefPubMed

26.

Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, Moustaid-Moussa N, Pasqualini F, Mantovani A, Ailhaud G, Amri EZ (2003) Characterization of the long pentraxin PTX3 as a TNF alpha-induced secreted protein of adipose cells. J Lipid Res 44:994–1000CrossRefPubMed

27.

Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, Vallell GD, Dejana E, Mantovani A, Introna M (1992) Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267:22190–22197PubMed

28.

Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, Romani L, Garlanda C, Mantovani A (2003) Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol 33:2886–2893CrossRefPubMed

29.

Norata GD, Garlanda C, Catapano AL (2010) The long petraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. Trends Cardiovasc Med 20:35–40CrossRefPubMed

30.

Lee GW, Lee TH, Vilcek J (1993) TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 150:1804–1812PubMed

31.

Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A (1994) Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 84:3483–3493PubMed

32.

Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, Cugno M, Iapichino G, Gattinoni L, Pesenti A, Mantovani A (2010) Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med 36:621–629CrossRefPubMed

Title: Implications of pentraxin 3 levels in patients with acute aortic dissection
Authors: Kenshiro Arao
Takayuki Fujiwara
Yousuke Taniguchi
Hiroyuki Jinnouchi
Harue Sasai
Mitsunari Matsumoto
Hiroshi Funayama
Junya Ako
Shin-ichi Momomura
Publication date: 01-03-2015
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 2/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-014-0470-2

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Implications of pentraxin 3 levels in patients with acute aortic dissection

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

The relationship between epicardial adipose tissue and ST-segment resolution in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Comparison of contemporary risk scores for predicting outcomes after surgery for active infective endocarditis

A low prevalence of sarcomeric gene variants in a Chinese cohort with left ventricular non-compaction

Seasonal variation in patients with acute heart failure: prognostic impact of admission in the summer

Bioresorbable scaffolds for the treatment of in-stent restenosis

Successful percutaneous transluminal angioplasty for the treatment of renovascular hypertension with an atrophic kidney

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page